![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myrexis to Provide Update on the Company's Cancer Metabolism Inhibitor at Upcoming Scientific Meetings
16 sept. 2010 11h31 HE
|
Myrexis, Inc.
SALT LAKE CITY, Sept. 16, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myrexis Reports Fiscal Year 2010 Results
09 sept. 2010 16h02 HE
|
Myrexis, Inc.
Robust Oncology Pipeline Advancing
Conference Call Today at 4:30pm ET
Upcoming Events
Announce final Phase 1 data for MPC-3100, a fully-synthetic Hsp90 inhibitor, in solid and hematological...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myrexis to Present at Rodman & Renshaw and UBS Conferences
02 sept. 2010 09h15 HE
|
Myrexis, Inc.
SALT LAKE CITY, Sept. 2, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myrexis to Hold Conference Call to Discuss Fiscal Year 2010 Results
31 août 2010 17h06 HE
|
Myrexis, Inc.
SALT LAKE CITY, Aug. 31, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
![Myrexis, Inc. Logo](http://www.globenewswire.com/fr/Attachment/LogoDisplay/218223?filename=218223.jpg&size=2)
Myriad Pharmaceuticals Formally Adopts Its Name Change to Myrexis, Inc. Effective July 1, 2010
30 juin 2010 18h23 HE
|
Myrexis, Inc.
SALT LAKE CITY, June 30, 2010 (GLOBE NEWSWIRE) -- Effective July 1, Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) will change its name to Myrexis, Inc. The name change was previously approved by...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myriad Pharmaceuticals Announces Intent to Focus on Oncology Portfolio
08 juin 2010 08h50 HE
|
Myrexis, Inc.
SALT LAKE CITY, June 8, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced several strategic initiatives to focus the Company's efforts on its oncology pipeline and to...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myriad Pharmaceuticals Announces Presentations of Phase 2 Data of Azixa(TM) Demonstrating Durable Responses in Patients With Glioblastoma Multiforme and Metastatic Melanoma at ASCO 2010
07 juin 2010 08h50 HE
|
Myrexis, Inc.
SALT LAKE CITY, June 7, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the presentation of clinical data from two separate Phase 2a combination drug studies of...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myriad Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
26 mai 2010 12h30 HE
|
Myrexis, Inc.
SALT LAKE CITY, May 26, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX), a company focused on discovering, developing and commercializing novel, small molecule drugs for the...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myriad Pharmaceuticals Announces Presentations at 2010 ASCO Annual Meeting
20 mai 2010 18h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, May 20, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced that it will be reporting data on its lead oncology candidate, Azixa™ (MPC-6827),...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myriad Pharmaceuticals Reports Third Quarter FY' 2010 Financial Results
17 mai 2010 16h18 HE
|
Myrexis, Inc.
SALT LAKE CITY, May 17, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today reported financial results for its third fiscal quarter ended March 31, 2010. The Company ended the...